Aclaris Therapeutics, Inc.

1.19 USD
-0.01 (-0.83%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aclaris Therapeutics, Inc. stock is down -2.46% since 30 days ago. The next earnings date is May 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 February’s closed higher than January.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. develops novel drug candidates for immune-inflammatory diseases in the United States. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa.